Alnylam Pharmaceuticals
ALNY
283 hedge funds and large institutions have $6.68B invested in Alnylam Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 109 increasing their positions, 99 reducing their positions, and 49 closing their positions.
131% more call options, than puts
Call options by funds: $123M | Put options by funds: $53.4M
10% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 99
1.5% more ownership
Funds ownership: 90.08% → 91.58% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
7% less funds holding
Funds holding: 304 → 283 (-21)
16% less capital invested
Capital invested by funds: $7.94B → $6.68B (-$1.25B)
39% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$99.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$79.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.2M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$46.1M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$77.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$72M |
| 3 |
JP Morgan Chase
New York
|
-$41.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.4M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20M |
ALNY Hedge Fund Activity: Q4 2018 in Review
283 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2018, worth a combined $6.68B — down 16% from $7.94B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ALNY and 30 opened new positions — a net loss of 19 holders — while 99 trimmed existing stakes and 109 added.
The largest buyer was Maverick Capital, adding an estimated $99.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $77.5M sold.
- 283 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2018, down from 304 in Q3 2018.
- Funds reported $6.68B of Alnylam Pharmaceuticals stock for Q4 2018, down 16% quarter-over-quarter.
- 30 funds opened new Alnylam Pharmaceuticals positions in Q4 2018 and 49 closed out, a net change of -19 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2018 was Maverick Capital, an estimated $99.4M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2018 was Point72 Asset Management, an estimated $77.5M sold.
Based on aggregated 13F filings for Q4 2018.